Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer

被引：0
|
作者：
Zhou, Q. [1 ,2 ]
Wu, Y. [1 ,2 ]
Chang, J. [3 ]
Wang, H. [3 ]
Fan, Y. [4 ]
Zhao, J. [5 ]
Wu, G. [6 ]
Sun, Y. [7 ]
Sun, M. [7 ]
Wang, X. [8 ]
Shi, H. [8 ]
Nian, W. [9 ]
Wang, K. [10 ]
Zheng, X. [11 ]
Qu, L. [12 ]
Yao, S. [12 ]
Shen, Z. [12 ]
Li, P. [12 ]
Yang, J. [12 ]
机构：
[1] Guangdong Prov PeopleS Hosp, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Beijing Canc Hosp, Beijing, Peoples R China
[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[7] Shandong Univ, Jinan Cent Hosp, Jinan, Peoples R China
[8] Gannan Med Univ, Affiliated Hosp 1, Ganzhou, Peoples R China
[9] Chongqing Canc Hosp, Chongqing, Peoples R China
[10] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[11] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[12] Cstone Pharmaceut Su Zhou Co Ltd, Suzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Pralsetinib; NSCLC; RET fusion;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.02
引用
收藏
页码：S889 / S890
页数：2
相关论文
共 50 条
  • [1] Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion plus non-small cell lung cancer
    Zhou, Q.
    Wu, Y-L.
    Zhao, J.
    Chang, J.
    Wang, H.
    Fan, Y.
    Wang, K.
    Wu, G.
    Nian, W.
    Gong, Y.
    Sun, Y.
    Sun, M.
    Wang, X.
    Shi, H.
    Zheng, X.
    Qin, M.
    Duan, X.
    Shen, Z.
    Yao, S.
    Yang, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1593 - S1593
  • [2] Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer
    Zhou, Qing
    Zhao, Jun
    Chang, Jianhua
    Wang, Huijie
    Fan, Yun
    Wang, Ke
    Wu, Gang
    Nian, Weiqi
    Sun, Yuping
    Sun, Meili
    Wang, Xiangcai
    Shi, Huaqiu
    Zheng, Xiangqian
    Yao, Sheng
    Qin, Mengmeng
    Shen, Zhenwei
    Yang, Jason
    Wu, Yi-Long
    [J]. CANCER, 2023, 129 (20) : 3239 - 3251
  • [3] Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy
    Zhou, Q.
    Wu, Y.
    Chang, J.
    Fan, Y.
    Zhao, J.
    Wu, G.
    Sun, Y.
    Wang, X.
    Nian, W.
    Wang, K.
    Zheng, X.
    Qu, L.
    Yao, S.
    Liu, K.
    Li, P.
    Yang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S235 - S235
  • [4] Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study
    Liao, Dehua
    Long, Minghui
    Zhang, Jiwen
    Wei, Xingyu
    Li, Fei
    Yan, Ting
    Yang, Desong
    [J]. LUNG CANCER, 2024, 196
  • [5] Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.
    Curigliano, Giuseppe
    Gainor, Justin F.
    Griesinger, Frank
    Thomas, Michael
    Subbiah, Vivek
    Baik, Christina S.
    Tan, Daniel Shao-Weng
    Lee, Dae Ho
    Misch, Daniel
    Garralda, Elena
    Kim, Dong-Wan
    Paz-Ares, Luis G.
    Mazieres, Julien
    Liu, Stephen V.
    Kalemkerian, Gregory Peter
    Houvras, Yariv
    Bowles, Daniel W.
    Mansfield, Aaron Scott
    Zalutskaya, Alena
    van der Wekken, Anthonie J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC)
    Besse, B.
    Griesinger, F.
    Curigliano, G.
    Thomas, M.
    Subbiah, V.
    Baik, C. S.
    Tan, D. S. W.
    Lee, D. H.
    Garralda, E.
    Kim, D-W.
    Van Der Wekken, A. J.
    Gainor, J.
    Paz-Ares, L.
    Liu, S. V.
    Bowles, D. W.
    Zalutskaya, A.
    Ruf, T.
    Rahman, A.
    Chen, G.
    Mazieres, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1083 - S1084
  • [7] Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC)
    Drilon, A.
    Subbiah, V.
    Gautschi, O.
    Tomasini, P.
    De Braud, F. G. M.
    Solomon, B.
    Tan, D. Shao-Weng
    Alonso, G.
    Wolf, J.
    Park, K.
    Goto, K.
    Soldatenkova, V.
    Szymczak, S.
    Barker, S.
    Puri, T.
    Lin, A. B.
    Loong, H. H. F.
    Besse, B.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S43 - S43
  • [8] Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC).
    Besse, Benjamin
    Drilon, Alexander E.
    Solomon, Benjamin J.
    Subbiah, Vivek
    Tan, Daniel Shao-Weng
    Park, Keunchil
    De Braud, Filippo G.
    Alonso, Guzman
    Wolf, Juergen
    Soldatenkova, Victoria
    Lin, Aimee K.
    French, Pearl Plernjit
    Goto, Koichi
    Gautschi, Oliver
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer
    Nguyen, Ly
    Monestime, Shanada
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 527 - 533
  • [10] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Gao, Ming
    Zhang, Xia
    Yan, Huan
    Sun, Decong
    Yang, Xuejiao
    Yuan, Fang
    Ju, Yanfang
    Wang, Lijie
    Wang, Jinliang
    Zhao, Wei
    Zhang, Dong
    Li, Lin
    Xu, Xiaoyun
    Ma, Junxun
    Hu, Yi
    Zhang, Xiaotao
    [J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
12345